[1]刘建中,邓霞,谭卫群,等.外用2%盐酸卡替洛尔和0.5%马来酸噻吗洛尔滴眼液治疗浅表性婴儿血管瘤临床观察[J].中国皮肤性病学杂志,2021,(03):277-282.[doi:10.13735/j.cjdv.1001-7089.202007183]
　LIU Jianzhong,DENG Xia,TAN Weiqun,et al.Topical 2% Carteolol Hydrochloride Eye Drops and 0.5% Timolol Maleate Eye Drops in the Treatment of Low or Medium Risk Infantile Hemangioma[J].The Chinese Journal of Dermatovenereology,2021,(03):277-282.[doi:10.13735/j.cjdv.1001-7089.202007183]
点击复制

外用2%盐酸卡替洛尔和0.5%马来酸噻吗洛尔滴眼液治疗浅表性婴儿血管瘤临床观察()
分享到：

《中国皮肤性病学杂志》[ISSN:1001-7089/CN:61-1197/R]

卷:
期数:
2021年03期
页码:
277-282
栏目:
临床经验
出版日期:
2021-03-01

文章信息/Info

Title:
Topical 2% Carteolol Hydrochloride Eye Drops and 0.5% Timolol Maleate Eye Drops in the Treatment of Low or Medium Risk Infantile Hemangioma
文章编号:
1001-7089(2021)03-0277-06
作者:
刘建中1; 邓霞2; 谭卫群3; 李萍1; 2; 李建红1; 罗珍1; 朱思虹 1; 石航1
1.广东省深圳市儿童医院皮肤科,广东 深圳 518038; 2.深圳遵义医学院珠海校区,广东 珠海519041; 3.广东省深圳市儿童医院心血管内科,广东 深圳 518038
Author(s):
LIU Jianzhong1; DENG Xia2; TAN Weiqun 3; LI Ping1; 2;  LI Jianhong 1;  LUO Zhen1;  ZHU Sihong 1;  SHI Hang1
(1. Department of Dermatology, Shenzhen Children's Hospital, Shenzhen 518038, China; 2.Zhuhai Campus of Zunyi Medical College, Zhuhai 519041,China; 3.Department of Cardiology, Shenzhen Children's Hospital, Shenzhen 518038, China)
关键词:
卡替洛尔;  噻吗洛尔;  外用;  中低风险;  浅表性;  增殖期;  婴儿血管瘤
Keywords:
Carteolol;  Timolol;  Topical;  Low or medium and risk;  Superficial;  Proliferation phase;  Infantile hemangioma
分类号:
R 739.5
DOI:
10.13735/j.cjdv.1001-7089.202007183
文献标志码:
B
摘要:
目的 观察外用2%盐酸卡替洛尔滴眼液和0.5%马来酸噻吗洛尔滴眼液治疗中低风险、浅表性、增殖期婴儿血管瘤的疗效及安全性。方法 采用随机开放平行对照试验将240例患者分为卡替洛尔组和噻吗洛尔组,最后分析201例患者的临床资料,分别对治疗后1个月、3个月和6个月时的疗效及不良反应进行组内和组间比较。 结果 卡替洛尔组(105例)和噻吗洛尔组(96例)治疗后1个月、3个月、6个月时的有效率分别为 18.10%和22.92%、63.81%和83.33%、82.86%和91.67%,表明随着用药时间的延长,有效率逐渐增高,疗程和疗效呈正相关(P均=0.00)。两组在用药后1个月和6个月时的有效率差异无统计学意义(P均>0.05),表明两种药物的起效时间和远期疗效无明显差别。总不良反应发生率:卡替洛尔组为6.67%(7/105),噻吗洛尔组为4.17%(4/96),差异未见统计学意义(P>0.05)。湿疹和溃疡为常见局部不良反应,其中卡替洛尔组7例(湿疹5例、溃疡2例)、噻吗洛尔组4例(湿疹3例、溃疡1例)。仅噻吗洛尔组的1例患者出现一过性不完全性房室传导阻滞,两组均未出现其他系统不良反应。结论 2%盐酸卡替洛尔滴眼液和0.5%马来酸噻吗洛尔滴眼液局部治疗中低风险、浅表性、增殖期婴儿血管瘤疗效肯定,随用药时间的延长,疗效增加。湿疹为局部常见不良反应,长期使用极少发生系统不良反应。两药均可作为婴儿血管瘤的治疗选择。
Abstract:
Objective To compare the efficacy and safety of 2% carteolol eye drops and 0.5% timolol eye drops in the treatment of low or medium risk, proliferative superficial infantile hemangioma.Methods A randomized, open parallel controlled trial was conducted in 240 cases of infantile hemangioma which were divided into carteolol and timolol group.The efficacy and adverse reactions at 1 month, 3 months and 6 months after treatment were analyzed.Results A total of 201 cases were analyzed.The effective rates of carteolol group(105 cases)and timolol group(96 cases)at 1 month, 3 months and 6 months were 18.10%/22.92%, 63.81%/83.33% and 82.86%/91.67%, respectively.The course of treatment was positively correlated with the curative effect(P = 0.00).There was no statistical difference in the effective rate between the two groups at 1 month and 6 months(P > 0.05).The incidence of total adverse reactions was 6.67%(7/105)in the carteolol group and 4.17%(4/96)in the timolol group, with no statistical difference(P > 0.05).Eczema and ulcer were common local adverse reactions, of which 7 cases were in the carteolol group(5 cases eczema, 2 cases ulcer)and 4 cases were in the timolol group(3 cases eczema, 1 case ulcer).Only 1 patient in timolol group presented transient incomplete atrioventricular block, and no other systemic adverse reactions occurred in both groups.Conclusion Both 2% carteolol eye drops and 0.5% timolol eye drops are effective in topical therapy of infantile hemangioma with low or medium risk, superficial and proliferative phase.Eczema is a common adverse reaction.Adverse systemic reactions are rare.

参考文献/References:

[1] Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al.Propranolol for severe hemangiomas of infancys[J].N Engl J Med,2008,358(24):2649-2651.
[2] Munden A, Butschek R, Tom WL, et al.Prospective study ofinfantile haemangiomas: incidence, clinical characteristics and association with placental anomalies[J].Br J Dermatol, 2014, 170(4): 907-913.
[3] Luu M, Frieden IJ.Haemangioma:clinical course,complications and management[J].Br J Dermatol,2013,169(1):20-30.
[4] Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, et al.A randomized, controlled trial of oral propranolol in infantile hemangioma[J].N Engl J Med, 2015, 372(8):735-746.
[5] 刘笑宇,李丽,尉莉,等.2%卡替洛尔溶液局部治疗婴儿血管瘤的疗效及安全性研究[J].临床皮肤科杂志, 2017, 46(1): 68-70.
[6] Achauer BM, Chang CJ, Vander Kam VM.Management of hemangioma of infancy:review of 245 patients[J].Plast Reconstr Surg, 1997, 99(5): 1301-1308.
[7] Chinnadurai S, Fonnesbeck C, Snyder KM, et al.Pharmacologic interventions for infantile h-emangioma:a meta-analysis[J].Pediatrics, 2016, 137(2): e20153896.
[8] Ovadia SA,Landy DC,Cohen ER,et al.Local administration of β-blockers for infantile h-emangiomas:a systematic review and meta-analysis[J].Ann Plast Surg,2015,74(2):256-262.
[9] Zheng L, Li Y.Effect of topical timolol on response rate and adverse events in infantile hemangioma:a meta-analysis[J].Arch Dermatol Res, 2018, 310(4): 261-269.
[10] Gan LQ,Wang H,Ni SL,et al.A prospective study of topical carteolol therapy in Chinese infants with superficial infantile hemangioma[J].Pediatr Dermatol, 2018, 35(1):121-122.
[11] 林晓,钱秋芳,黄迎,等.噻吗洛尔和卡替洛尔外用治疗婴幼儿血管瘤疗效观察[J].国际皮肤性病学杂志,2016,42(6): 441-443.
[12] Borok J, Gangar P, Admani S, et al.Safety and efficacy of topical timolol treatment of infantile haemangioma: a prospective trial[J].Br J Dermatol, 2018, 178(1):e51-e52.
[13] Püttgen K, Lucky A, Adams D, et al.Topical timolol maleate treatment of infantile hemangiomas[J].Pediatrics, 2016, 138(3): e20160355.
[14] Chakkittakandiyil A, Phillips R, Frieden IJ, et al.Timolol maleate 0.5% or 0.1% gelforming solution for infantile hemangiomas:a retrospective, multicenter,cohort study[J].Pediatr, 2012, 29(1):28e31.
[15] Kunzi-Rapp K.Topical propranolol therapy for infantile hemangiomas[J].Pediatr Dermatol, 2012, 29(2): 154-159.
[16] Qiu Y, Yang J, Chen M, et al.A prospective self-controlled study of topical timolol 0.5% cream for large superficial infantile hemangiomas[J].J Dermatol, 2015, 42(4): 363-366.

相似文献/References:

[1]冉玉平,徐小茜,冉昕,等.伊曲康唑口服液治愈婴儿血管瘤1例:皮肤镜监测血管瘤消退情况[J].中国皮肤性病学杂志,2017,(01):45.[doi:10.13735/j.cjdv.1001-7089.201607074]
　RAN Yu-ping,XU Xiao-xi,RAN Xin,et al.A Case of Infantile Hemangioma Successfully Treated by Itraconazole Oral Solution: Dermoscopy Monitory the Vascular Regression[J].The Chinese Journal of Dermatovenereology,2017,(03):45.[doi:10.13735/j.cjdv.1001-7089.201607074]

备注/Memo

备注/Memo:
[基金项目] 深圳市卫生和计划生育委员会(SZFZ2017065)
[通信作者] 李萍,E-mail: liping20081110@126.com
更新日期/Last Update: 2021-02-10